We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
-8.27%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$122M
AUM Growth
-$9.45M
Cap. Flow
+$7.15M
Cap. Flow %
5.85%
Top 10 Hldgs %
89.53%
Holding
22
New
5
Increased
2
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
APLT
Applied Therapeutics
APLT
+$4.42M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.17M
3
DOW icon
Dow Inc
DOW
+$1.58M
4
CTVA icon
Corteva
CTVA
+$807K
5
ALDX icon
Aldeyra Therapeutics
ALDX
+$341K

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$2.06M
2
DD icon
DuPont de Nemours
DD
+$1.39M

Sector Composition

Rank Sector Weight
1 Healthcare 84.73%
2 Financials 5.56%
3 Materials 3.78%
4 Consumer Staples 3.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
1
Corbus Pharmaceuticals
CRBP
$170M
$34.6M 28.29%
166,196
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$32.8M 26.88%
749,815
– –
ABEO icon
3
Abeona Therapeutics
ABEO
$345M
$11.3M 9.23%
94,391
– –
BX icon
4
Blackstone
BX
$104B
$6.8M 5.56%
153,000
– –
KRYS icon
5
Krystal Biotech
KRYS
$9.88B
$5.92M 4.85%
147,090
-62,896
-30% -$2.06M
MO icon
6
Altria Group
MO
$122B
$4.26M 3.49%
90,000
– –
APLT
7
DELISTED
Applied Therapeutics
APLT
$3.85M 3.15%
+467,071
New +$4.42M
EIGR
8
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$3.71M 3.04%
11,675
+9,167
+366% +$3.17M
ALDX icon
9
Aldeyra Therapeutics
ALDX
$91.7M
$3.18M 2.6%
529,390
+45,294
+9% +$341K
KBA icon
10
KraneShares Bosera MSCI China A 50 Connect Index ETF
KBA
$150M
$2.97M 2.43%
96,000
– –
AVXL icon
11
Anavex Life Sciences
AVXL
$222M
$2.44M 2%
724,205
– –
DD icon
12
DuPont de Nemours
DD
$18.6B
$2.25M 1.84%
23,900
-11,639
-33% -$1.39M
GLMD icon
13
Galmed Pharmaceuticals
GLMD
$3.94M
$1.51M 1.24%
1,145
– –
DOW icon
14
Dow Inc
DOW
$21.6B
$1.48M 1.21%
+30,000
New +$1.58M
ENTX icon
15
Entera Bio
ENTX
$101M
$1.47M 1.21%
475,540
– –
MTEM
16
DELISTED
Molecular Templates, Inc.
MTEM
$951K 0.78%
7,594
– –
CTVA icon
17
Corteva
CTVA
$59.7B
$887K 0.73%
+30,000
New +$807K
ECOR icon
18
electroCore
ECOR
$51.4M
$794K 0.65%
26,481
– –
SNGX icon
19
Soligenix
SNGX
$5.5M
$595K 0.49%
3,494
– –
OTRK
20
DELISTED
Ontrak
OTRK
$281K 0.23%
+162
New +$242K
LPCN icon
21
Lipocine
LPCN
$17.1M
$97K 0.08%
2,941
– –
NTBL
22
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$28K 0.02%
+611
New +$27.8K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Knoll Capital Management held 22 positions worth $122M, down 7.2% from $132M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Knoll Capital Management deployed $7.15M of net new capital in Q2 2019, opening 5 new positions and adding to 2 existing holdings. Its largest new stake was Applied Therapeutics: 467,071 shares worth $3.85M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Krystal Biotech, an estimated $2.06M trimmed.

  • Knoll Capital Management's largest Q2 2019 buy was Applied Therapeutics: 467,071 shares worth $3.85M.
  • Knoll Capital Management added most to Eiger BioPharmaceuticals, Inc. in Q2 2019, an estimated $3.17M increase.
  • Knoll Capital Management's biggest Q2 2019 reduction was Krystal Biotech, cutting an estimated $2.06M.
  • Knoll Capital Management's ten largest holdings make up 90% of its $122M portfolio in Q2 2019.
  • Knoll Capital Management opened 5 new positions and closed 0 in Q2 2019.
  • Knoll Capital Management's portfolio value fell 7.2% quarter-over-quarter to $122M.

Based on Knoll Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.